Interviews with Pharma and Biotech Global Leaders
Refine Search
Pharmaceutical
Jennifer Miller is the founding president of Bioethics International (BEI), a US-based non-profit organization which aims to improve the ethics and transparency of health care innovation and delivery. 29 June 2016
Biotechnology
The boss of one of Europe’s leading biotech companies tells The Pharma Letter that it cannot now consider teaming up with UK researchers because of fears that such partnerships will lose European Union (EU) funding. 27 June 2016
Pharmaceutical
UK-based Sinclair Pharma has had some hugely challenging decisions to make as it has undergone a strategic review over the last 18 months. 25 June 2016
Biosimilars
The biosimilars pipeline of the South Korean company Samsung Bioepis would be highly impressive if it belonged to a long-established, world-leading pharma giant. 22 June 2016
Biotechnology
There has been a lot of excitement about the potential of biosimilars at the European League Against Rheumatism Annual Congress (EULAR) in London this week. 10 June 2016
Biotechnology
If the innovative approach being championed by Boston-based biopharma company Berg delivers to patients what it promises to, then it could spell the end for a number of features which characterize pharma today. 31 May 2016
Biotechnology
Eliot Forster, who became chief executive of Immunocore in January 2015, speaks to The Pharma Letter’s Katie Osborne on why he is so excited about ImmTACs and how the company is working around the clock to get its lead product – IMCgp100 - to a group of patients with no other treatment options. 27 May 2016
Biotechnology
Keith Thompson, the chief executive of the Cell and Gene Therapy Catapult (CGT), tells The Pharma Letter's Guy Martin that the launch of Islexa UK, a company aimed at bringing islet transplant therapy to thousands of diabetes patients, is evidence of the very real difference this new field of medicine can make to patients’ lives in the near future. 23 May 2016
Pharmaceutical
It goes without saying that being successful in pharma requires innovation, particularly with a number of big companies facing damaging patent expirations in the next year or two. 23 May 2016
Biotechnology
Following news this week that Cardiff-based cell therapy company Cell Therapy Ltd has signed a partnership agreement giving Japan’s Daiichi Sankyo the rights to its heart failure drug Heartcel, the company’s chief executive, Ajan Reginald, spoke to TPL’s Katie Osborne about the decision. 11 May 2016
Pharmaceutical
Achieving commercial success and leading new innovations at the same time as proving your credentials as ethical, patient-focused and community-minded is what so many big pharma companies are striving for. 9 May 2016
Biotechnology
Stephen O’Hara is chief executive of OptiBiotix Health, a UK-based biotech which has been interesting big pharma recently with its Lactobacillus plantarum strain, a statin-free cholesterol pill. He spoke to the Pharma Letter... 4 May 2016
Pharmaceutical
Chief executive of pain specialists Purdue Pharma Mark Timney talks to the Pharma Letter’s Katie Osborne about the company’s hopes and ambitions to move away from opioids and invest in different therapeutic areas. 19 April 2016
Biotechnology
Senior director of business development at the US-based company, Ultragenyx, Rob Anstey, takes time out of his busy schedule at the recent Bio Europe spring conference in Stockholm to speak to The Pharma Letter’s Katie Osborne about the company’s plans and ambitions. 7 April 2016
Pharmaceutical
GlaxoSmithKline's head of worldwide medical affairs, Danie du Plessie, speaks exclusively to the Pharma Letter's Katie Osborne during the 14th annual eyeforpharma conference in Barcelona about rebuilding patient trust. 16 March 2016
Pharmaceutical
The newly-appointed chief executive of US-based firm Avanir Pharmaceuticals has set out his vision in an exclusive interview with The Pharma Letter’s Katie Osborne. 29 January 2016
Biotechnology
Chief executive of Avacta Life Sciences, Alastair Smith, talks to the Pharma Letter about the company's focus on Affimer binders and their potential applications. 18 January 2016
Generics
The Pharma Letter's Anjali Shukla caught up with Jayant Manglik, president at Religare Securities in New Delhi to discuss the current trends in the industry. 14 December 2015
Biotechnology
India-based Vyome Biosciences plans a regulatory filing by the end of the year with US Food and Drug Administration for its lead molecule (VB 1953), which targets the vast drug resistant acne prescription market, co-founder and chief executive N Venkat told The Pharma Letter in an exclusive interview. 30 November 2015
Pharmaceutical
With the US Senate launching an investigation into the steep drug price hikes, the ongoing debate on the pharmaceutical industry’s pricing mechanism is once again under the scanner. 5 November 2015
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze